Cytomegalovirus Clinical Trial
Official title:
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
This pilot study is to assess whether using CytoGam® in combination with ganciclovir is more effective in reducing the CMV viral load over time, as compared to standard treatment with IV ganciclovir only. Serial blood samples are drawn to measure the amount of CMV viral load weekly, while the subject is receiving treatment with ganciclovir, or ganciclovir + CytoGam®. Additional CMV viral load blood sampling (CMV DNA capture qualitative testing only) will occur weekly thereafter until the subject is 8 weeks from the time of CMV diagnosis or until the CMV infection is no longer detectable, whichever is longer duration.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01195571 -
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
|
Phase 1 | |
| Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
| Active, not recruiting |
NCT05575492 -
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
| Completed |
NCT00456664 -
CMV Disease and IRIS in HIV-1 Infected Persons
|
N/A | |
| Completed |
NCT04840199 -
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
|
Phase 2 | |
| Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02452229 -
Review of Human Herpes Viruses in Burns
|
N/A | |
| Completed |
NCT01160081 -
Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis
|
N/A | |
| Completed |
NCT00467532 -
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
|
N/A | |
| Terminated |
NCT03127787 -
Clinical Performance Evaluation of DxN CMV Assay
|
||
| Completed |
NCT00366717 -
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
|
N/A | |
| Completed |
NCT00815802 -
Detection of Human Cytomegalovirus in the Saliva
|
N/A | |
| Completed |
NCT01646645 -
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Suspended |
NCT00668798 -
Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms
|
N/A | |
| Completed |
NCT00330018 -
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
|
Phase 3 | |
| Completed |
NCT02083042 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT01895049 -
Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
|
Phase 4 | |
| Completed |
NCT01162330 -
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
|
N/A | |
| Completed |
NCT01008540 -
Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients
|
N/A |